难治性脓毒性休克的临床定义标准:SCCM与ESICM联合德尔菲共识
该共识由SCCM与ESICM召集56名多国多专业重症专家,经五轮德尔菲流程对34条声明进行投票,最终29条中13条达成共识。共识认定难治性脓毒性休克应以器官功能障碍标志物、组织灌注标志物(乳酸、毛细血管再充盈时间)、初始复苏后液体反应性评估以及去甲肾上腺素等效剂量大于0.5 µg/kg/min的血管活性药物使用为临床标准。重症超声(CCUS)是唯一达成共识的诊断方式,用于怀疑混合性休克时评估。该共识为难治性脓毒性休克的诊断、管理、预后判断和未来研究提供了框架。
要点
- 共识将去甲肾上腺素等效剂量大于0.5 µg/kg/min列为难治性脓毒性休克的血管活性药物标准(75.0%同意,3轮)。
- 乳酸(94.6%同意,2轮)和毛细血管再充盈时间(76.8%同意,2轮)被选为组织灌注标志物。
- 初始复苏后液体反应性评估达成共识(92.9%同意,5轮),液体无反应性是定义条件之一。
- 重症超声(CCUS)是唯一达成共识的诊断方式(92.9%同意,3轮),用于怀疑混合性休克时评估。
- 器官功能障碍标志物亦达成共识(75%,2轮),纳入综合临床标准体系。
适用人群与场景
- 脓毒性休克患者,处于初始复苏后阶段,用于判断是否为难治性脓毒性休克。
诊断标准与关键阈值
- 难治性脓毒性休克临床标准包括:器官功能障碍标志物、组织灌注标志物(乳酸、毛细血管再充盈时间)、初始复苏后液体反应性评估、去甲肾上腺素等效剂量大于0.5 µg/kg/min的血管活性药物使用。
- 难治性脓毒性休克特征为:脓毒性休克患者液体无反应,需要去甲肾上腺素碱等效剂量大于0.5 µg/kg/min,且乳酸浓度持续升高和或毛细血管再充盈时间延长。
- 怀疑混合性休克时进行重症超声(CCUS)评估。
研究设计与关键结果
- 设计:文献回顾、专家小组立场声明及德尔菲轮次,共识定义为至少75%小组成员在7点Likert量表最高或最低三个水平上同意或不同意,或基于单选或多选题回答。
- 专家组:SCCM与ESICM召集的多国、多专业、多学科重症专家,发出57份邀请,56人参与。
- 德尔菲流程:进行五轮德尔菲过程以达到共识和稳定性;指导委员会提出34条声明,其中5条在第2轮后被专家小组否决;从8个领域选出的29条声明中,13条达成共识。
- 达成共识的领域与比例:器官功能障碍标志物(75%,2轮)、组织灌注(91.1%,2轮)包括乳酸(94.6%,2轮)和毛细血管再充盈时间(76.8%,2轮)、初始复苏后液体反应性评估(92.9%,5轮)、去甲肾上腺素等效剂量大于0.5 µg/kg/min的血管活性药物使用(75.0%,3轮)。
- 重症超声(CCUS)是唯一达成共识的诊断方式(92.9%,3轮)。
证据类型、等级与局限
- 证据类型:SCCM与ESICM联合德尔菲共识(指南/共识)。
- 共识方法:五轮德尔菲流程,共识阈值至少75%同意或不同意。
- 局限:原文未报告局限性。
对床旁实践的改变
- 共识提出13条标准构建难治性脓毒性休克定义,床旁可依据乳酸持续升高和或毛细血管再充盈时间延长、液体无反应性、去甲肾上腺素等效剂量大于0.5 µg/kg/min及怀疑混合性休克时CCUS评估来识别难治性脓毒性休克。
指南或共识出处
- Clinical criteria for the definition of refractory septic shock: a joint Delphi consensus from the Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM), Intensive Care Med.
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: A definition of refractory septic shock is necessary to guide diagnosis, management, prognostication, research, and future guidelines for this most severe form of the disease. We sought to achieve consensus on clinical criteria that would be used to define refractory septic shock.
DESIGN: Review of literature, expert panel position statements, and Delphi rounds with an international expert group.
SETTING: Consensus was defined as having at least 75% of panellists in agreement or disagreement on the three highest or lowest levels of a 7-point Likert scale or based on responses to single- or multiple-choice questions, respectively.
SUBJECTS: A panel of multinational, multiprofessional, and multidisciplinary critical care experts assembled by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine (57 invitations and 56 participants).
MEASUREMENTS AND MAIN RESULTS: A five-round Delphi process was conducted for consensus and stability. The steering committee proposed 34 statements, and five of them were rejected by panel experts after round 2. Among 29 statements selected from eight domains, consensus was reached for 13. The panel agreed on the need for a comprehensive consensus set of clinical criteria for refractory septic shock. Markers of organ dysfunction (75%, 2 rounds), tissue perfusion (91.1%, 2 rounds) including lactate (94.6%, 2 rounds) and capillary refill time (76.8%, 2 rounds), assessment of fluid responsiveness after initial resuscitation (92.9%, 5 rounds), and use of vasoactive drugs at norepinephrine equivalents greater than 0.5 µg/kg/min (75.0%, 3 rounds) were selected as clinical criteria of refractory septic shock. The use of critical care ultrasound (CCUS) (92.9%, 3 rounds) was the single diagnostic modality that reached a consensus-based agreement.
CONCLUSIONS: A consensus for 13 criteria to frame the definition of refractory septic shock was reached. Refractory septic shock is characterised by persistently elevated lactate concentrations and or prolonged capillary refill time in patients with septic shock who are fluid unresponsive, require a norepinephrine base equivalent dose greater than 0.5 µg per kilogram per minute, and undergo CCUS assessment when mixed shock is suspected.
参考来源
- Leone M, Myatra SN, Dugar S, et al. Clinical criteria for the definition of refractory septic shock: a joint Delphi consensus from the Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM). Intensive Care Med. 2026. PMID: 41874620. doi:10.1007/s00134-026-08344-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。